23andMe Holding Co. (ME)
Chart Events
Performance Outlook
| Previous Close | 0.9058 |
| Open | 0.9164 |
| Bid | 0.8852 x 900 |
| Ask | 0.8860 x 900 |
| Day's Range | 0.8700 - 0.9164 |
| 52 Week Range | 0.8700 - 3.5000 |
| Volume | |
| Avg. Volume | 2,608,962 |
| Market Cap | 426.943M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ME
Related Research
- 23andMe Holding Co.Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.RatingFair ValueEconomic Moatlast yearMorningstar
GlobeNewswire23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignanciesSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meet
- GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disease is common About one in 13 African Americans have the sickle cell trait. Many are unaware that they are carriers or what it means to be a carrier of the sickle cell trait SOUTH SAN FRANCISCO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human gen
- Yahoo Finance Video
23andMe receives FDA approval to test for cancer variants
23andMe (ME) shares are rising after the personal genetics company was given FDA approval on testing for cancer variants in customers. Yahoo Finance Live checks out 23andMe's stock action and the benefits it could see from leaning more into the health space.
